Case Reports in Radiology

Case Reports in Radiology / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 6265175 |

Kazuki Yoshida, Masao Miyagawa, Teruhito Kido, Kana Ide, Yoshifumi Sano, Yoshifumi Sugawara, Hiroyuki Takahata, Nobuya Monden, Mitsuko Furuya, Teruhito Mochizuki, "Parotid Oncocytoma as a Manifestation of Birt-Hogg-Dubé Syndrome", Case Reports in Radiology, vol. 2018, Article ID 6265175, 7 pages, 2018.

Parotid Oncocytoma as a Manifestation of Birt-Hogg-Dubé Syndrome

Academic Editor: Bruce J. Barron
Received08 Jan 2018
Accepted07 May 2018
Published03 Jun 2018


Birt-Hogg-Dubé syndrome (BHD) is a rare autosomal dominant disease characterized by skin fibrofolliculomas, pulmonary cysts, spontaneous pneumothoraces, and renal cancers. Oncocytomas are benign epithelial tumors that are also rare. Recently, there have been a few case reports of BHD with a parotid oncocytoma that appears to have a BHD phenotype. Here we document the eighth known case and describe the magnetic resonance imaging features of the parotid oncocytoma, which mimicked Warthin’s tumor. Radiologists should be aware of the association between these rare disorders.

1. Introduction

Birt-Hogg-Dubé syndrome (BHD) is a rare autosomal dominant disease characterized by skin fibrofolliculomas, pulmonary cysts, spontaneous pneumothoraces, and renal cancers [1]. In 1977, Birt, Hogg, and Dubé reported on a group of patients from single kindred who had multiple fibrofolliculomas with trichodiscomas and acrochordons [2]. This hereditary condition was later named Birt-Hogg-Dubé syndrome. In 2002, Nickerson et al. identified the BHD gene, which codes a protein called folliculin [3]. The BHD gene is now known as the folliculin gene (FLCN).

Patients with BHD often have renal tumors. Pavlovich et al. reported that 34 (27%) of 124 patients with BHD had renal tumors with variable histology, most commonly hybrid oncocytic tumors, and chromophobe renal cell carcinomas [4]. However, there are few reported cases of BHD with parotid gland oncocytoma. Here we present a rare case of a patient with this association.

2. Case History

A 44-year-old woman presented to our hospital complaining of right lower facial swelling and pain around the parotid gland. Her past medical history was unremarkable. However, she had a family history of pneumothoraces in her father and brother. Magnetic resonance (MR) imaging showed a 35 mm diameter mass in the superficial lobule of the right parotid gland. The lesion appeared hypointense on both T1-weighted MR imaging (T1WI) and T2-weighted imaging (T2WI). On fat-saturated T2WI, the masses appeared hyperintense when compared with the native parotid gland tissue but hypointense on contrast-enhanced T1WI with fat saturation. The lesion was hyperintense on axial diffusion-weighted imaging with a b-value of 1000 s/mm2 and a low apparent diffusion coefficient (Figure 1). The lesion was suspected to be Warthin’s tumor, and a right superficial parotidectomy was performed accordingly.

There was a well-circumscribed, solid, mahogany-colored nodule measuring 3.7 × 2.8 × 2.4 cm in the superficial parotidectomy specimen (Figure 2(a)). Microscopically, the nodule was an encapsulated tumor containing oncocytic cells. These cells formed solid clusters or trabecular patterns, separated by thin strands of fibrovascular stroma (Figure 2(b)) and were round in shape with centrally placed nuclei and clear cytoplasm. Neither necrosis nor capsular invasion was observed. Cytoplasmic granules enriched with glycogen were present but there was no mucin on periodic acid-Schiff staining (data not shown). Although the morphology was comparable to oncocytoma of the kidney, radiologic examination excluded the possibility of a metastatic renal tumor, and immunostaining for PAX-2 and CD10, which are markers for renal cell carcinoma, was negative (data not shown). The pathologic diagnosis was clear cell oncocytoma.

One and a half years later, the patient presented to hospital again, this time with mild dyspnea. Physical examination revealed decreased breath sounds on the right side. A computed tomography (CT) scan showed a right pneumothorax and multiple cysts. The cysts were located in the medial basilar regions of the lung fields bilaterally and were ellipsoid in shape and variable in size. Some of the cysts abutted the proximal portions of the lower pulmonary arteries (Figure 3). The patient was strongly suspected to have BHD and was subsequently referred for genetic counseling. Informed consent was obtained from the patient for FLCN genetic testing, which was performed on genomic DNA extracted from peripheral leukocytes. Duplication of cytosine was identified in the C8 tract of exon 11 (c.1285dupC), confirming the diagnosis of BHD. The patient’s brother, who had an episode of pneumothorax, asked for genetic testing and was found to have the same mutation as the proband (data not shown).

3. Discussion

BHD is a rare disease and there are some reports of its prevalence. In North America, 102 BHD-affected families have been reported by the National Cancer Institute group [6, 15]. In Asia, 312 affected individuals from 120 Japanese BHD families have been reported [16]. However, information regarding the manifestations of BHD apart from pulmonary cysts, renal tumors, and cutaneous manifestations is limited. Oncocytomas are rare benign epithelial tumors, accounting for only 0.5%–1.5% of all salivary gland tumors. The parotid gland is the site most often affected, accounting for 78%–84% of salivary gland oncocytomas [12]. These tumors are slightly more prevalent in women than in men and usually occur in the seventh to ninth decades of life [14].

Lieu et al. reported the first case of BHD with parotid oncocytoma in a 56-year-old man [5]. Lindor et al. then reported a 45-year-old Caucasian woman with BHD who presented with multiple oncocytic parotid tumors [8]. Pradella et al. also reported a parotid oncocytoma that had arisen in a patient with BHD [9]. In a report by Schmidt et al. in 2005 on 219 BHD-affected individuals, four parotid gland tumors were documented in 2 men and 2 women. Three of those tumors were classified as oncocytoma [6]. In 2011, Maffé et al. reported on 19 BHD-affected individuals, including a 53-year-old man with bilateral parotid oncocytoma. There was a relative reduction of the wild-type signal from the parotid oncocytoma in this patient, who was heterozygous for the FLCN mutation. They reported that parotid oncocytoma should be considered as a component manifestation of BHD [7]. To the best of our knowledge, our patient is the eighth reported case of BND with parotid oncocytoma. The previous seven reports and our present case are summarized in Table 1.

CaseYearFirst author
and region
Age at diagnosis, years
MutationPathology of parotid tumor (Age at diagnosis)SkinLung
(Age, years)
(Age, years)
Family history

12000Liu et al. [5]
North America
56/MN/AOncocytoma (55)FFPTX,
-Sister (PTX, LC)

2-42005Schmidt et al [6]
North America

52011Maffé et al. [7]
53/Mc.347 dup A
(exon 5)
(32, right; 43, left)
Father (hybrid CCC/on with CCC component accounting for 60% of the lesion and sigmoid adenocarcinoma)

62012Lindor et al. [8]
North America
45/Fc.779+1 G>T
(exon 7i)
Oncocytic neoplasm (45)FF--Maternal grandfather (prostate cancer), maternal grandmother (bladder cancer, lung cancer)

72013Pradella et al. [9]
N/Ac.347 dupA
(exon 5)

82016Present report
Yoshida et al.
(exon 11)
Clear cell
oncocytoma (44)
-PTX (45)
-Father (PTX)
Brother (PTX)

M: male: F: female; FF: fibrofolliculoma; TD: trichodiscomas; PTX: pneumothorax; LC: lung cysts; CCC: clear cell carcinoma; N/A: not available.

FLCN encodes the protein folliculin (FLCN), which acts as a tumor suppressor. FLCN forms a complex with FLCN-interacting protein 1 (FNIP1) and FNIP1 homologue FNIP2, which interacts with 5’-AMP-activated protein kinase and regulates signaling of the mammalian target of rapamycin [17, 18].

The clinical characteristics of BHD are thought to be age-related. Skin lesions usually develop after the age of 20 years. Pulmonary cysts and pneumothoraces are often found in young adult patients aged 20–30 years, and renal cell tumors are more likely to develop after the age of 40 years. Therefore, BHD should be considered in patients who develop repeated spontaneous pneumothoraces and have skin fibrofolliculomas [1, 17]. Abdominal imaging is recommended at least every 3 years in the clinical follow-up of BHD. We prefer MR imaging to CT as it avoids exposure to radiation [18].

The MR imaging reports on parotid oncocytomas suggest that these lesions are hypointense on both T1WI and T2WI [10, 14], are hyperintense on diffusion-weighted imaging, and have low apparent diffusion coefficient values. Dynamic contrast-enhanced MR images show early enhancement with early washout [10]. Parotid oncocytomas also show high uptake of 18F-fluorodeoxyglucose on positron emission tomography (Table 2) [11]. Oncocytomas and Warthin’s tumors have very similar features on imaging and therefore are very difficult to differentiate [19]. However, oncocytomas have unique imaging features that have led to them being known as “vanishing tumors” and may help in the diagnosis. Oncocytomas are hard to detect on fat-saturated T2 and T1 postcontrast MR images because of the similarity of intensity of the tumor and the parenchyma, hence the term vanishing tumor. Oncocytes have a low free water content and a lipid-rich membrane. If the amount of lipids in the tumor is approximately equal to that in the normal parotid gland tissue, the vanishing phenomenon occurs [13]. However, in our patient, the lesion appeared slightly hyperintense on fat-saturated T2WI and hypointense on contrast-enhanced and fat-saturated T1WI. The histology was that of a clear cell oncocytoma, which contains large amounts of glycogen and lipid that is different from that of normal oncocytes. A mixed oncocytoma/pleomorphic adenoma is hyperintense on fat-saturated T2WI and contrast-enhanced, fat-saturated T1WI [13]. These different MR imaging features may reflect the histopathologic findings. The previous seven case reports did not describe the imaging findings in detail. It is uncertain if the MR findings of solitary oncocytoma are different from those of oncocytoma associated with BHD; therefore, further investigation is needed.

No.First author, yearAge/Sex
BHD or not
Pathology Size

1Kasai et al. [10]

2Shah et al. [11]
76/MOnc20HomogeneousN/AN/AN/AN/AN/AIntense FDG uptake

Tan et al. [12]
7 female
3 male
Onc6–666 Heterogeneous
4 Homogeneous

Patel et al. [13]
6 female
3 male
8 Onc
13–34N/A9 HypoN/AN/A8 Iso
1 Hyper
8 Iso
1 Hyper

22Lindor et al. [8]

23Sepúlveda et al. [14]

24This report
Yoshida et al.
Clear cell

M: male; F: female; Hypo: hypointense; Iso: isointense; Hyper: hyperintense; N/A: not available; T1WI: T1-weighted imaging; T2WI: T2-weighted imaging; DWI: diffusion-weighted images; ADC: apparent diffusion coefficient; T2WI FS: T2-weighted imaging with fat saturation; T1WI CE FS: postcontrast T1-weighted imaging with fat saturation; FDG-PET: 18F-fluorodeoxyglucose positron emission tomography; Onc: oncocytes. Mixed oncocytoma/pleomorphic adenoma.

Tobino et al. reported that multiple, irregular-shaped cysts of various sizes with lower medial lung zone predominance were characteristic features of BHD on CT [20]. Cysts abutting or including the proximal portion of the lower pulmonary arteries or veins are also highly probable in BHD (Figure 3). Our patient had these features, which were very helpful in making a diagnosis of BHD.

In conclusion, we describe the eighth confirmed case in the literature of parotid oncocytoma in BHD, which mimicked Warthin’s tumor on MR imaging. Parotid oncocytoma appears to be one of the phenotypes in BHD. It is difficult to distinguish between oncocytomas and Warthin’s tumors; however, radiologists should be aware of this association and consider parotid oncocytoma as a differential diagnosis if they detect a parotid mass similar to Warthin’s tumor in BHD. If additional imaging is to be recommended, a dedicated renal-protocol MRI would be the choice, alone or in addition to chest CT.

Informed consent to publish this report was obtained from the patient.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.


The authors thank Dr. Shojirou Morinaga, Department of Pathology, Hino Municipal Hospital, Hino, Japan, for making the pathological diagnosis in this patient.


  1. F. H. Menko, M. A. van Steensel, S. Giraud et al., “Birt-Hogg-Dubé syndrome: diagnosis and management,” The Lancet Oncology, vol. 10, no. 12, pp. 1199–1206, 2009. View at: Publisher Site | Google Scholar
  2. A. R. Birt, G. R. Hogg, and W. J. Dube, “Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons,” JAMA Dermatology, vol. 113, no. 12, pp. 1674–1677, 1977. View at: Publisher Site | Google Scholar
  3. M. L. Nickerson, M. B. Warren, J. R. Toro et al., “Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome,” Cancer Cell, vol. 2, no. 2, pp. 157–164, 2002. View at: Publisher Site | Google Scholar
  4. C. P. Pavlovich, R. L. Grubb III, K. Hurley et al., “Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome,” The Journal of Urology, vol. 173, no. 5, pp. 1482–1486, 2005. View at: Publisher Site | Google Scholar
  5. V. Liu, T. Kwan, and E. H. Page, “Parotid oncocytoma in the Birt-Hogg-Dubé syndrome,” Journal of the American Academy of Dermatology, vol. 43, no. 6, pp. 1120–1122, 2000. View at: Publisher Site | Google Scholar
  6. L. S. Schmidt, M. L. Nickerson, M. B. Warren et al., “Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome,” American Journal of Human Genetics, vol. 76, no. 6, pp. 1023–1033, 2005. View at: Publisher Site | Google Scholar
  7. A. Maffé, B. Toschi, G. Circo et al., “Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations,” Clinical Genetics, vol. 79, no. 4, pp. 345–354, 2011. View at: Publisher Site | Google Scholar
  8. N. M. Lindor, J. Kasperbauer, J. E. Lewis, and M. Pittelkow, “Birt-Hogg-Dubé syndrome presenting as multiple oncocytic parotid tumors,” Hereditary Cancer in Clinical Practice, vol. 10, no. 1, article 13, 2012. View at: Publisher Site | Google Scholar
  9. L. M. Pradella, M. Lang, I. Kurelac et al., “Where Birt-Hogg-Dubé meets Cowden Syndrome: Mirrored genetic defects in two cases of syndromic oncocytic tumours,” European Journal of Human Genetics, vol. 21, no. 10, pp. 1169–1172, 2013. View at: Publisher Site | Google Scholar
  10. T. Kasai, K. Motoori, T. Hanazawa, Y. Nagai, and H. Ito, “MR imaging of multinodular bilateral oncocytoma of the parotid gland,” European Journal of Radiology Extra, vol. 63, no. 3, pp. 97–100, 2007. View at: Publisher Site | Google Scholar
  11. V. N. Shah and B. F. Branstetter, “Oncocytoma of the parotid gland: a potential false-positive finding on 18F-FDG PET,” American Journal of Roentgenology, vol. 189, no. 4, pp. 212–214, 2007. View at: Publisher Site | Google Scholar
  12. T. J. Tan and T. Y. Tan, “CT features of parotid gland oncocytomas: A study of 10 cases and literature review,” American Journal of Neuroradiology, vol. 31, no. 8, pp. 1413–1417, 2010. View at: Publisher Site | Google Scholar
  13. N. D. Patel, A. Van Zante, D. W. Eisele, H. R. Harnsberger, and C. M. Glastonbury, “Oncocytoma: The vanishing parotid mass,” American Journal of Neuroradiology, vol. 32, no. 9, pp. 1703–1706, 2011. View at: Publisher Site | Google Scholar
  14. I. Sepúlveda, E. Platín, M. L. Spencer et al., “Oncocytoma of the parotid gland:a case report and review of the literature,” Case Reports in Oncology, vol. 7, no. 1, pp. 109–116, 2014. View at: Publisher Site | Google Scholar
  15. J. R. Toro, M.-H. Wei, and G. M. Glenn, “BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports,” Journal of Medical Genetics, vol. 45, no. 6, pp. 321–331, 2008. View at: Publisher Site | Google Scholar
  16. M. Furuya, M. Yao, R. Tanaka et al., “Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birt–Hogg–Dubé syndrome,” Clinical Genetics, vol. 90, no. 5, pp. 403–412, 2016. View at: Publisher Site | Google Scholar
  17. M. Furuya and Y. Nakatani, “Birt–Hogg–Dubé syndrome: clinicopathological features of the lung,” Journal of Clinical Pathology, vol. 66, no. 3, pp. 178–186, 2013. View at: Publisher Site | Google Scholar
  18. L. Stamatakis, A. R. Metwalli, L. A. Middelton, and W. Marston Linehan, “Diagnosis and management of BHD-associated kidney cancer,” Familial Cancer, vol. 12, no. 3, pp. 397–402, 2013. View at: Publisher Site | Google Scholar
  19. Y. Araki and R. Sakaguchi, “Synchronous oncocytoma and Warthin's tumor in the ipsilateral parotid gland,” Auris Nasus Larynx, vol. 31, no. 1, pp. 73–78, 2004. View at: Publisher Site | Google Scholar
  20. K. Tobino, Y. Gunji, M. Kurihara et al., “Characteristics of pulmonary cysts in Birt-Hogg-Dubé syndrome: Thin-section CT findings of the chest in 12 patients,” European Journal of Radiology, vol. 77, no. 3, pp. 403–409, 2011. View at: Publisher Site | Google Scholar

Copyright © 2018 Kazuki Yoshida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.